IDT Biologika GmbH

Dessau-Roßlau, Germany

Viral Vaccines (live, inactivated, BSL-2) AAV Adenoviral Vectors Lentiviral Vectors Gene & Immune Therapeutics Oncolytic Viruses Monoclonal Antibodies Recombinant Proteins / Biosimilars Sterile Fill-Finish (liquid, lyophilized, vials, pre-filled syringes)

1 confirmed programs · 1 sponsors

56.2

Signal Score

○ FDA Inspections ✓ Clinical Trials (1) ○ SEC Filings ✓ Press (4) ○ EMA GMP ○ MHRA GMP

Quick Facts: IDT Biologika GmbH

Signal Score: 56.2/100
Quality Compliance: Assessment pending
Headquarters: Dessau-Roßlau, Germany
Modalities: Viral Vaccines (live, inactivated, BSL-2), AAV, Adenoviral Vectors, Lentiviral Vectors, Gene & Immune Therapeutics, Oncolytic Viruses, Monoclonal Antibodies, Recombinant Proteins / Biosimilars, Sterile Fill-Finish (liquid, lyophilized, vials, pre-filled syringes)
Active Programs: 1 confirmed from ClinicalTrials.gov across 1 sponsors
Data Sources: FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By: CDMO Signal — independent CDMO intelligence platform

About IDT Biologika GmbH

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance —

No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.

FDA InspectionsNo US records on file

No FDA inspection records found for this manufacturer

Quality score requires FDA inspection data

Operations

1 active programs across 1 sponsors · Modalities: Viral Vaccines (live, inactivated, BSL-2), Sterile Fill-Finish (liquid, lyophilized, vials, pre-filled syringes), Lentiviral Vectors, Adenoviral Vectors, Gene & Immune Therapeutics, Oncolytic Viruses, Recombinant Proteins / Biosimilars, Monoclonal Antibodies, AAV

Programs 1

Sponsors1

ModalitiesViral Vaccines (live, inactivated, BSL-2), AAV, Adenoviral Vectors, Lentiviral Vectors, Gene & Immune Therapeutics, Oncolytic Viruses, Monoclonal Antibodies, Recombinant Proteins / Biosimilars, Sterile Fill-Finish (liquid, lyophilized, vials, pre-filled syringes)

1 active programs across 1 sponsors

Modalities: Viral Vaccines (live, inactivated, BSL-2), Sterile Fill-Finish (liquid, lyophilized, vials, pre-filled syringes), Lentiviral Vectors, Adenoviral Vectors, Gene & Immune Therapeutics, Oncolytic Viruses, Recombinant Proteins / Biosimilars, Monoclonal Antibodies, AAV

Source: ClinicalTrials.gov facility matching

NCT04119440 Safety and Immunogenicity of the Candidate Vaccine... PHASE1 Completed

Source: ClinicalTrials.gov · Retrieved Jul 11, 2026

Financial Stability

Profile-based financial assessment

SEC FilingsPrivate company

Private company

Financial assessment: 60.0/100

Capacity

Profile-based capacity assessment

Recent Press4 articles

Broad modality coverage (9 modalities)

Clinical Activity 1 studies

NCT04119440 Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS PHASE1 Completed

Source: ClinicalTrials.gov · Retrieved Jul 11, 2026

Recent News 4 articles

news Wed, 05 No

IDT Biologika Accelerates Global CDMO Expansion Manufacturing capabilities highlighted through consecutive participation in WVC, CPHI and BIO-Europe 2025 - PR Newswire

Source →

news Tue, 27 Fe

Takeda taps Biological E to ⁠ramp up Qdenga manufacturing capacity on quest to make 100M doses a year - Fierce Pharma

Source →

news Tue, 21 Oc

From the experts: How to successfully implement Annex 1 regulations - Pharmaceutical Technology

Source →

news Thu, 27 Ju

SK Bioscience begins 'globalization' push, paying $244M for majority stake in contract manufacturer IDT Biologika - Fierce Pharma

Source →